| |  Online-Ressource |
|---|
| Verfasst von: | Averna, Maurizio [VerfasserIn]  |
|---|
| | Banach, Maciej [VerfasserIn] |
|---|
| | Bruckert, Eric [VerfasserIn] |
|---|
| | Drexel, Heinz [VerfasserIn] |
|---|
| | Farnier, Michel [VerfasserIn] |
|---|
| | Gaita, Dan [VerfasserIn] |
|---|
| | Magni, Paolo [VerfasserIn] |
|---|
| | März, Winfried [VerfasserIn] |
|---|
| | Masana, Luis [VerfasserIn] |
|---|
| | Mello e Silva, Alberto [VerfasserIn] |
|---|
| | Reiner, Zeljko [VerfasserIn] |
|---|
| | Ros, Emilio [VerfasserIn] |
|---|
| | Vrablik, Michal [VerfasserIn] |
|---|
| | Zambon, Alberto [VerfasserIn] |
|---|
| | Zamorano, Jose L. [VerfasserIn] |
|---|
| | Stock, Jane K. [VerfasserIn] |
|---|
| | Tokgözoğlu, Lale S. [VerfasserIn] |
|---|
| | Catapano, Alberico L. [VerfasserIn] |
|---|
| Titel: | Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients |
|---|
| Titelzusatz: | a statement from a European Atherosclerosis Society Task Force |
|---|
| Verf.angabe: | Maurizio Averna, Maciej Banach, Eric Bruckert, Heinz Drexel, Michel Farnier, Dan Gaita, Paolo Magni, Winfried März, Luis Masana, Alberto Mello e Silva, Zeljko Reiner, Emilio Ros, Michal Vrablik, Alberto Zambon, Jose L. Zamorano, Jane K. Stock, Lale S. Tokgözoğlu, Alberico L. Catapano |
|---|
| E-Jahr: | 2021 |
|---|
| Jahr: | May 2021 |
|---|
| Umfang: | 11 S. |
|---|
| Fussnoten: | Gesehen am 15.11.2021 |
|---|
| Titel Quelle: | Enthalten in: Atherosclerosis |
|---|
| Ort Quelle: | Amsterdam [u.a.] : Elsevier Science, 1970 |
|---|
| Jahr Quelle: | 2021 |
|---|
| Band/Heft Quelle: | 325(2021) vom: Mai, Seite 99-109 |
|---|
| ISSN Quelle: | 1879-1484 |
|---|
| Abstract: | Background and aims - This European Atherosclerosis Society (EAS) Task Force provides practical guidance for combination therapy for elevated low-density lipoprotein cholesterol (LDL-C) and/or triglycerides (TG) in high-risk and very-high-risk patients. - Methods - Evidence-based review. - Results - Statin-ezetimibe combination treatment is the first choice for managing elevated LDL-C and should be given upfront in very-high-risk patients with high LDL-C unlikely to reach goal with a statin, and in primary prevention familial hypercholesterolaemia patients. A proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor may be added if LDL-C levels remain high. In high and very-high-risk patients with mild to moderately elevated TG levels (>2.3 and < 5.6 mmol/L [>200 and < 500 mg/dL) on a statin, treatment with either a fibrate or high-dose omega-3 fatty acids (icosapent ethyl) may be considered, weighing the benefit versus risks. Combination with fenofibrate may be considered for both macro- and microvascular benefits in patients with type 2 diabetes mellitus. - Conclusions - This guidance aims to improve real-world use of guideline-recommended combination lipid modifying treatment. |
|---|
| DOI: | doi:10.1016/j.atherosclerosis.2021.03.039 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.atherosclerosis.2021.03.039 |
|---|
| | Volltext: https://www.sciencedirect.com/science/article/pii/S0021915021001623 |
|---|
| | DOI: https://doi.org/10.1016/j.atherosclerosis.2021.03.039 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | 2019 ESC/EAS Dyslipidaemia Guidelines |
|---|
| | Combination treatment |
|---|
| | High-risk |
|---|
| | LDL cholesterol |
|---|
| | Lipid goals |
|---|
| | Triglycerides |
|---|
| K10plus-PPN: | 1777457874 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients / Averna, Maurizio [VerfasserIn]; May 2021 (Online-Ressource)
